Graft versus Host Disease (GVHD) is a rare disorder that can strike persons whose immune system is deficient
Graft Versus Host Disease (GvHD)
Allogeneic stem cell
transplantation and reduced-intensity allogeneic stem cell transplantation both
carry the risk of graft-versus-host disease (GVHD). A patient receives stem
cells from a donor or donated umbilical cord blood during an allogeneic stem cell
transplant. When the recipient's healthy cells (the host) are attacked and
damaged by the donor's T cells (the graft), it results in GVHD. Mild, moderate,
or severe graft-versus-host disease are all possible. It might even be fatal in
some circumstances.
According to Coherent Market Insights the Graft
Versus Host Disease (GvHD) Market Global Industry Insights, Trends,
Outlook, and Opportunity Analysis, 2022-2028
A patient undergoing an
allogeneic stem cell transplant will receive some form of GVHD prevention,
unless the patient's donor is an identical twin. This might entail taking T
cells out of the donor graft or giving the graft's T cells medication to
suppress them so they don't attack the patient's cells. There is no established
protocol for the prevention of GVHD, and different drug regiments are utilised
at various institutions. Mild to severe GVHD can exist. After a transplant,
many patients will experience some GVHD symptoms.
GVHD is not always a bad thing.
Your physician might view mild GVHD as advantageous if your transplant was
performed to treat blood cancer. It's a sign that the new cells are actively
eradicating any remaining cancer cells in your body. A patient's risk of their
cancer coming back after transplant may be reduced if they have some GVHD.
Comments
Post a Comment